Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
admin 20th April 2018 Uncategorised 0Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening. Rejected by the FDA earlier this year, the copycat needs a small bridging study before the agency can take another look, CEO Vas Narasimhan said.
More: Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Source: fierce